U.S., Aug. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07112274) titled 'Empagliflozin on Patients With Preserved Heart Failure' on Aug. 01.
Brief Summary: The proposed research in this application will investigate the effect of empagliflozin on cardiac remodeling in patients with heart failure with preserved ejection fraction.
Study Start Date: Oct. 01, 2022
Study Type: INTERVENTIONAL
Condition:
Heart Failure
Intervention:
DRUG: Empagliflozin 10 MG
Treatment group will receive empagliflozin 10 mg tablet once daily
OTHER: Placebo Tablet
control group will receive placebo tablet.
Recruitment Status: COMPLETED
Sponsor: Damanhour University
Information provided by (Responsible Party): Rehab Werid...